AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications

 AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications

AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications

Shots:

  • Dragonfly to receive upfront, milestones and royalties on licensed therapies. AbbVie to get an exclusive option to license global intellectual property rights to develop and commercialize therapies developed during the collaboration
  • Dragonfly will utilize its TriNKET platform for developing therapies targeting multiple autoimmune and oncology indications
  • Dragonfly’s novel TriNKET technology acts by enhancing immunotherapy utilizing NK cells, thus harnessing the body’s innate immune system to bring breakthrough cancer therapies

Click here to­ read full press release/ article | Ref: PRNewswire | Image: The Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post